University of Oxford

🇬🇧United Kingdom

Country: 🇬🇧United Kingdom

Ownership: Private

Established: 1096-01-01

Employees: 10K

Market Cap: -

Website: http://www.ox.ac.uk

Clinical Trials

Investigating a Vaccine Against COVID-19

Phase 2

Active, not recruiting

Conditions: Coronavirus

Interventions: Biological: ChAdOx1 nCoV-19 (qPCR)
Biological: ChAdOx1 nCoV-19 (Abs 260)
Biological: ChAdOx1 nCoV-19 0.5mL prime plus boost
Biological: ChAdOx1 nCoV-19 (Abs 260) + 2.2x10^10vp (qPCR) boost
Biological: Two dose ChAdOx1 nCoV-19/Covishield 0.25mL & 0.5mL
Biological: Two dose ChAdOx1 nCoV-19/Covishield 0.5mL
Biological: MenACWY vaccine
Biological: Two dose MenACWY vaccine min. 4 weeks apart
Biological: Two dose MenACWY vaccine

First Posted Date: 2020-05-26

Last Posted Date: 2023-08-01

Lead Sponsor: University of Oxford

Target Recruit Count: 12390

Registration Number: NCT04400838

Locations: 🇬🇧
University Hospital Southampton NHS Foundation Trust, Southampton, Hampshire, United Kingdom
🇬🇧
University College London Hospitals NHS Foundation Trust, London, United Kingdom
🇬🇧
John Radcliffe Hospital, Oxford, United Kingdom

and more 17 locations

The Effect of a Single Dose of Lamotrigine on Brain Function in Healthy Volunteers

Not Applicable

Completed

Conditions: Healthy

Interventions: Drug: Lamotrigine
Drug: Placebos

First Posted Date: 2020-05-21

Last Posted Date: 2020-05-21

Lead Sponsor: University of Oxford

Target Recruit Count: 36

Registration Number: NCT04396938

Locations: 🇬🇧
University of Oxford, Oxford, Oxfordshire, United Kingdom

Neonatal Complications of Coronavirus Disease (COVID-19)

Conditions: Neonatal COVID-19 Disease

Interventions: Other: No intervention - exposure is to COVID-19

First Posted Date: 2020-05-13

Last Posted Date: 2020-05-13

Lead Sponsor: University of Oxford

Target Recruit Count: 500

Registration Number: NCT04386109

Locations: 🇬🇧
Imperial College, London, United Kingdom

A Multicentre Open-label Two-arm Randomised Superiority Clinical Trial of Azithromycin Versus Usual Care In Ambulatory COVID19 (ATOMIC2)

Phase 3

Completed

Conditions: COVID-19

Interventions: Drug: Azithromycin Capsule

First Posted Date: 2020-05-11

Last Posted Date: 2021-05-06

Lead Sponsor: University of Oxford

Target Recruit Count: 298

Registration Number: NCT04381962

Locations: 🇬🇧
Horton General Hospital, Banbury, Oxfordshire, United Kingdom
🇬🇧
John Radcliffe Hospital, Oxford, Oxfordshire, United Kingdom
🇬🇧
Ninewells Hospital, Dundee, Scotland, United Kingdom

and more 2 locations

Randomised Evaluation of COVID-19 Therapy

Phase 3

Recruiting

Conditions: Severe Acute Respiratory Syndrome

Interventions: Drug: Lopinavir-Ritonavir
Biological: Convalescent plasma
Biological: Immunoglobulin
Drug: Corticosteroid
Drug: Synthetic neutralising antibodies
Drug: Empagliflozin
Drug: Anakinra
Drug: High Dose Corticosteroid
Drug: Sotrovimab
Drug: Paxlovid
Drug: Baloxavir Marboxil
Drug: Hydroxychloroquine
Drug: Azithromycin
Drug: Tocilizumab
Drug: Aspirin
Drug: Dimethyl fumarate
Drug: Colchicine
Drug: Baricitinib
Drug: Oseltamivir
Drug: Molnupiravir

First Posted Date: 2020-05-11

Last Posted Date: 2024-01-05

Lead Sponsor: University of Oxford

Target Recruit Count: 70000

Registration Number: NCT04381936

Locations: 🇻🇳
Oxford University Clinical Research Unit, Centre for Tropical Medicine, Ho Chi Minh City, Vietnam
🇬🇭
Kumasi Center for Collaborative Research in Tropical Medicine KNUST, Kumasi, Ghana
🇮🇳
Indian Council of Medical Research, Division of Epidemiology and Communicable Diseases, New Delhi, India

and more 4 locations

Sulforaphane Supplementation Study

Not Applicable

Conditions: Obesity
Non-Alcoholic Fatty Liver Disease
Metabolic Syndrome

Interventions: Dietary Supplement: Sulforaphane extract

First Posted Date: 2020-04-28

Last Posted Date: 2022-06-07

Lead Sponsor: University of Oxford

Target Recruit Count: 60

Registration Number: NCT04364360

Locations: 🇬🇧
Oxford Centre for Diabetes, Endocrinology and Metabolism, Oxford, Oxfordshire, United Kingdom

Ivermectin Safety in Small Children

Phase 2

Recruiting

Conditions: Scabies

Interventions: Drug: Oral ivermectin
Drug: Permethrin Cream
Other: Placebo tablet
Other: Placebo cream

First Posted Date: 2020-04-02

Last Posted Date: 2024-05-21

Lead Sponsor: University of Oxford

Target Recruit Count: 399

Registration Number: NCT04332068

Locations: 🇧🇷
Alfredo da Matta Tropical Dermatology Foundation (FUAM), Manaus, Brazil
🇰🇪
Kenya Medical Research Institute, Kisumu, Kenya
🇬🇲
MRC Unit The Gambia, Banjul, Gambia

A Study of a Candidate COVID-19 Vaccine (COV001)

Phase 1

Active, not recruiting

Conditions: Coronavirus

Interventions: Biological: ChAdOx1 nCoV-19
Biological: MenACWY
Biological: ChAdOx1 nCoV-19 full boost
Biological: ChAdOx1 nCoV-19 half boost
Biological: MenACWY boost
Biological: ChAdOx1 nCoV-19 0.5mL boost
Biological: ChAdOx1 nCoV-19 0.5mL (3.5-6.5x10^10vp) late vaccine (LV)
Biological: ChAdOx1 nCoV-19 0.5mL (3.5-6.5x10^10vp) late vaccine two (LVT)
Drug: Paracetamol

First Posted Date: 2020-03-27

Last Posted Date: 2023-08-01

Lead Sponsor: University of Oxford

Target Recruit Count: 1090

Registration Number: NCT04324606

Locations: 🇬🇧
University Hospital Southampton NHS Foundation Trust, Southampton, Hampshire, United Kingdom
🇬🇧
University Hospitals Bristol and Weston NHS Foundation Trust, Bristol, United Kingdom
🇬🇧
St Georges University Hospital NHS Foundation Trust, London, United Kingdom

and more 3 locations